An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Clinical trial NCT06951217 · RECRUITING

Trial details

NCT number: NCT06951217
Sponsor: Avalyn Pharma Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Progressive Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF)

Start date: 2025-04-17
Primary completion: 2031-12-31
Enrollment: 340

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.